Literature DB >> 27528456

The role of surgery in the therapeutic approach of gastric cancer liver metastases.

Aikaterini Mastoraki1, Christina Benetou2, Sotiria Mastoraki2, Ioannis S Papanikolaou2, Nikolaos Danias2, Vassilios Smyrniotis2, Nikolaos Arkadopoulos2.   

Abstract

Gastric cancer (GC) currently prevails as the second cause of death by malignancy worldwide. Estimations suggest that 35 % of affected patients appear with synchronous distant metastases. The vast majority of patients present with hepatic metastatic disease, sometimes accompanied by synchronous peritoneal and lung dissemination. The disease mostly remains asymptomatic at an early stage, with few reported cases of incidental abdominal discomfort. As the cancer advances, symptoms such as nausea or vomiting arise, along with indigestion and dysphagia, blood loss in the form of melena or hematemesis, as well as anorexia and weight loss. Having spread to the liver, it also causes jaundice due to hepatomegaly and general inanition. Despite recent research on the therapeutic strategies against GC metastatic disease, surgical resection appears the only potentially curative approach. Unfortunately, the majority of patients are not eligible to undergo surgical intervention. With regard to treatment modalities of the advanced stage disease, the role of metastasectomy is still debatable and quite unclear, while prolonged survival was succeeded only under certain specific circumstances. Systemic chemotherapy remains however another option, as well as local management in the form of cryotherapy, radiofrequency ablation, or transcatheter arterial chemoembolization. The aims of this review were to evaluate the results of surgical treatment for metastatic GC with special reference to the extent of its histological spread and to present the recent literature in order to provide an update on the current concepts of advanced surgical management of this entity. Relevant publications in the last two decades are briefly reviewed.

Entities:  

Keywords:  Diagnostic modalities; Gastric cancer; Liver metastatic disease; Surgical strategy; Therapeutic approach

Mesh:

Year:  2016        PMID: 27528456     DOI: 10.1007/s12664-016-0683-7

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  42 in total

1.  Prognostic factors for survival in patients with hepatic recurrence after curative resection of gastric cancer.

Authors:  Si-Eun Hwang; Doo-Hyun Yang; Chan-Young Kim
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

2.  Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.

Authors:  M H Whiteford; H M Whiteford; L F Yee; O A Ogunbiyi; F Dehdashti; B A Siegel; E H Birnbaum; J W Fleshman; I J Kodner; T E Read
Journal:  Dis Colon Rectum       Date:  2000-06       Impact factor: 4.585

3.  Predictive factors improving survival after gastric and hepatic surgical treatment in gastric cancer patients with synchronous liver metastases.

Authors:  Jing Liu; Jing-Hui Li; Ru-Jun Zhai; Bo Wei; Ming-Zhe Shao; Lin Chen
Journal:  Chin Med J (Engl)       Date:  2012-01       Impact factor: 2.628

4.  Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis.

Authors:  J Ward; K S Naik; J A Guthrie; D Wilson; P J Robinson
Journal:  Radiology       Date:  1999-02       Impact factor: 11.105

Review 5.  Current status and progress in gastric cancer with liver metastasis.

Authors:  Jing Liu; Lin Chen
Journal:  Chin Med J (Engl)       Date:  2011-02       Impact factor: 2.628

6.  Clinicopathological features and outcome of hepatic resection for liver metastasis from gastric cancer.

Authors:  Akio Saiura; Nobutaka Umekita; Satoru Inoue; Tsuyoshi Maeshiro; Sachio Miyamoto; Yuichi Matsui; Masahiro Asakage; Masatsugu Kitamura
Journal:  Hepatogastroenterology       Date:  2002 Jul-Aug

7.  Chemotherapy and resection for gastric cancer with synchronous liver metastases.

Authors:  Lei Chen; Ming-Quan Song; Hui-Zhong Lin; Lin-Hua Hao; Xiang-Jun Jiang; Zi-Yu Li; Yu-Xin Chen
Journal:  World J Gastroenterol       Date:  2013-04-07       Impact factor: 5.742

8.  Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection: a multi-institutional study of the indications for resection.

Authors:  Ken Shirabe; Mitsuo Shimada; Takashi Matsumata; Hidefumi Higashi; Yohichi Yakeishi; Shigeki Wakiyama; Yasuharu Ikeda; Takuhiro Ezaki; Shingo Fukuzawa; Kenji Takenaka; Keishi Kishikawa; Tetsuo Ikeda; Ken-ichi Taguchi; Yoshihiko Maehara; Keizo Sugimachi
Journal:  Hepatogastroenterology       Date:  2003 Sep-Oct

9.  Role of metastasectomy on overall survival of patients with metastatic gastric cancer.

Authors:  Seung Wook Yang; Min Gyu Kim; Ju Hee Lee; Sung Joon Kwon
Journal:  J Gastric Cancer       Date:  2013-12-31       Impact factor: 3.720

10.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

View more
  6 in total

Review 1.  Resection of Large Metachronous Liver Metastasis with Gastric Origin: Case Report and Review of the Literature.

Authors:  Ionut Negoi; Alexandru Runcanu; Sorin Paun; Ruxandra Irina Negoi; Mircea Beuran
Journal:  Cureus       Date:  2016-10-03

2.  Morusin inhibits cell proliferation and tumor growth by down-regulating c-Myc in human gastric cancer.

Authors:  Feng Wang; Dunke Zhang; Jingxin Mao; Xiao-Xue Ke; Rui Zhang; Chao Yin; Ning Gao; Hongjuan Cui
Journal:  Oncotarget       Date:  2017-07-14

3.  A Case of Complete Remission from Advanced Gastric Adenocarcinoma with Synchronous Liver Metastasis in Response to EOX Chemotherapy.

Authors:  Zhi-Jun Yan; Jia-Xin Wang; You-Yi Liu; Zhen-Hui Li; Li-Juan Zhang; Ping Gan; Xiao Han; Li-Kun Luan; You-Guo Dai
Journal:  Case Rep Gastrointest Med       Date:  2018-10-23

4.  Tanshinone IIA inhibits cell proliferation and tumor growth by downregulating STAT3 in human gastric cancer.

Authors:  Yongjun Zhang; Shuguang Guo; Jian Fang; Bojian Peng; Yuan Zhang; Tiansheng Cao
Journal:  Exp Ther Med       Date:  2018-08-02       Impact factor: 2.447

5.  Establishment and Analysis of an Individualized Immune-Related Gene Signature for the Prognosis of Gastric Cancer.

Authors:  Mengying Li; Wei Cao; Bingqian Huang; Zhipeng Zhu; Yaxin Chen; Jiawei Zhang; Guodong Cao; Bo Chen
Journal:  Front Surg       Date:  2022-01-31

Review 6.  ZFAS1: a novel tumor-related long non-coding RNA.

Authors:  Dan Dong; Zhongyi Mu; Chenghai Zhao; Mingli Sun
Journal:  Cancer Cell Int       Date:  2018-09-03       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.